{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-24-000005","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2024-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.981590+00:00","generated_at":"2026-06-06T20:05:38.191148+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"BeiGene appoints ex-Sanofi CEO Olivier Brandicourt to board; director Malley resigns","bullets":["Thomas Malley resigned from BeiGene board and audit committee on Jan 22, 2024; no disagreement with company operations.","Olivier Brandicourt, former Sanofi CEO and Blackstone Life Sciences Senior Advisor, appointed to board on Jan 23, 2024.","Brandicourt will serve on audit committee and receive annual cash comp of $65,000 plus $17,500 for committee service, and pro-rated option valued at $400,000.","He fills the vacancy created by Malley's resignation and will stand for election at the 2024 annual meeting in June."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-24-000005","json":"https://secwatch.observer/filing/0001651308-24-000005.json","markdown":"https://secwatch.observer/filing/0001651308-24-000005.md","text":"https://secwatch.observer/filing/0001651308-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/0001651308-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/bgne-20240122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:05:38.191148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0c89d553b","claim":"Olivier Brandicourt was appointed as Director at BeOne Medicines Ltd..","evidence_excerpt":"On January 23, 2024, the Board appointed Olivier Brandicourt, M.D. to the Board to fill the vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/0001651308-24-000005-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cd8cdcb54a","claim":"Thomas Malley resigned as Director at BeOne Medicines Ltd..","evidence_excerpt":"On January 22, 2024, Thomas Malley resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000005/0001651308-24-000005-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}